Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Dangerous interaction between the antibiotic ciprofloxacin and the muscle relaxant tizanidine

16.12.2004


Researchers from Finland have found that the antibiotic ciprofloxacin (brand names Ciproxin, Ciprofloxacin etc.) greatly increases the concentrations of tizanidine (Sirdalud, Zanaflex) in blood. Concomitant use of ciprofloxacin and tizanidine results in severe and prolonged decrease in blood pressure and greatly enhances central nervous system effects.



This previously unrecognised interaction can be dangerous, particularly in elderly patients, and the concomitant use of the two agents must be avoided. Tizanidine is widely used for treatment of musculoskeletal pain associated with increased muscle tension or chronic spasticity.

The concentrations of tizanidine in blood were increased on average 10-fold by ciprofloxacin in a carefully controlled study in healthy volunteer subjects. The volunteers ingested the usual 500-mg dose of ciprofloxacin (or placebo) twice daily for 3 days, and then a single 4-mg dose of tizanidine. The interaction was observed in each of the ten subjects; the greatest increase in tizanidine concentration by ciprofloxacin was 24-fold.


Ciprofloxacin enhanced greatly also the effects of tizanidine. In particular, the decrease in systolic (“upper”) blood pressure, to the level of 90-mm Hg or even less, was an alarming finding. Such hypotension can be dangerous, eg in elderly subjects and in patients who have heart problems. Also the central nervous system effects of tizanidine were greatly enhanced by ciprofloxacin: all ten subjects were somnolent and dizzy for about 3 hours after tizanidine intake.

Both tizanidine and ciprofloxacin are widely used drugs in many countries. E.g. in Finland (population 5 200 000) about 136 000 patients used tizanidine and about 60 000 patients used ciprofloxacin during the year 2003. Therefore, it is likely that ciprofloxacin and tizanidine can be coadministrered, if the risk of the interaction is not recognised by clinicians.

The interaction results from inhibition of the liver metabolism of tizanidine by ciprofloxacin. The same mechanism causes a serious interaction also between the antidepressant fluvoxamine and tizanidine, which was uncovered earlier this year. Further studies are being carried out to study whether there are other unrecognised interactions between tizanidine and other drugs.

The study was conducted at the Department of Clinical Pharmacology, University of Helsinki, by an independent group of researchers led by Professor Pertti J Neuvonen, MD, PhD, and Dr. Janne T Backman, MD, PhD. The study was published in the December issue of Clinical Pharmacology & Therapeutics, the leading scientific journal within the clinical pharmacology and therapeutics area.

Paivi Lehtinen | alfa
Further information:
http://www.helsinki.fi

More articles from Life Sciences:

nachricht Retracing the Roots of Fungal Symbioses
27.02.2015 | Lawrence Berkeley National Laboratory

nachricht Moving molecule writes letters
27.02.2015 | Technische Universitaet Muenchen

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Anzeige

Anzeige

Event News

European Geosciences Union meeting: programme online, provisional press conference topics

26.02.2015 | Event News

Round Table on Solar Energy Research

18.02.2015 | Event News

40th FEBS Congress 2015 – The Biochemical Basis of Life

09.02.2015 | Event News

 
Latest News

Researchers create self-reconstructive metal wire utilizing electric field trapping of gold nanoparticles

27.02.2015 | Power and Electrical Engineering

Climate-Change Clues From the Turtles of Tropical Wyoming

27.02.2015 | Ecology, The Environment and Conservation

Pockets of Calm Protect Molecules Around a Supermassive Black Hole

27.02.2015 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>